Corbus Pharma Q2 loss $10M; CRB-701 shows 44% ORR in mUC; cash runway through Q3 2027

Corbus Pharmaceuticals Holdings, Inc.

2024-Q2 EPS reported -$1.75

Net loss of $10.0M ($0.90 per diluted share) for Q2 2024, compared to net loss of $8.8M ($2.05 per share) in Q2 2023.
Cash and investments of $147M at June 30; raised $28.8M additional through Aug 1; cash runway extended through Q3 2027.
CRB-701 Phase 1 data: 44% ORR and 78% DCR in metastatic urothelial cancer; 43% ORR and 86% DCR in cervical cancer at doses ≥1.2mg/kg.
US/EU Phase 1 dose escalation for CRB-701 commenced April 2024; completion expected Q4 2024; data presentation Q1 2025.
CRB-913 Phase 1 start expected Q1 2025; CRB-601 Phase 1 start expected Q4 2024; both pre-clinical data support advancement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.